221 related articles for article (PubMed ID: 30886153)
21. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
22. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
[TBL] [Abstract][Full Text] [Related]
23. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.
Wang Z; Kim TB; Peng B; Karam J; Creighton C; Joon A; Kawakami F; Trevisan P; Jonasch E; Chow CW; Canales JR; Tamboli P; Tannir N; Wood C; Monzon F; Baggerly K; Varella-Garcia M; Czerniak B; Wistuba I; Mills G; Shaw K; Chen K; Sircar K
Clin Cancer Res; 2017 Nov; 23(21):6686-6696. PubMed ID: 28710314
[No Abstract] [Full Text] [Related]
24. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.
Xu X; Hou Y; Yin X; Bao L; Tang A; Song L; Li F; Tsang S; Wu K; Wu H; He W; Zeng L; Xing M; Wu R; Jiang H; Liu X; Cao D; Guo G; Hu X; Gui Y; Li Z; Xie W; Sun X; Shi M; Cai Z; Wang B; Zhong M; Li J; Lu Z; Gu N; Zhang X; Goodman L; Bolund L; Wang J; Yang H; Kristiansen K; Dean M; Li Y; Wang J
Cell; 2012 Mar; 148(5):886-95. PubMed ID: 22385958
[TBL] [Abstract][Full Text] [Related]
25. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma.
Lichner Z; Scorilas A; White NM; Girgis AH; Rotstein L; Wiegand KC; Latif A; Chow C; Huntsman D; Yousef GM
Am J Pathol; 2013 Apr; 182(4):1163-70. PubMed ID: 23416164
[TBL] [Abstract][Full Text] [Related]
26. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
27. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
28. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Gerlinger M; Horswell S; Larkin J; Rowan AJ; Salm MP; Varela I; Fisher R; McGranahan N; Matthews N; Santos CR; Martinez P; Phillimore B; Begum S; Rabinowitz A; Spencer-Dene B; Gulati S; Bates PA; Stamp G; Pickering L; Gore M; Nicol DL; Hazell S; Futreal PA; Stewart A; Swanton C
Nat Genet; 2014 Mar; 46(3):225-233. PubMed ID: 24487277
[TBL] [Abstract][Full Text] [Related]
29. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
30. m
Zhong J; Liu Z; Cai C; Duan X; Deng T; Zeng G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33574053
[TBL] [Abstract][Full Text] [Related]
31. Genomics and clinical correlates of renal cell carcinoma.
Mitchell TJ; Rossi SH; Klatte T; Stewart GD
World J Urol; 2018 Dec; 36(12):1899-1911. PubMed ID: 30099580
[TBL] [Abstract][Full Text] [Related]
32. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
33. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
34. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
35. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
Sankin A; Hakimi AA; Mikkilineni N; Ostrovnaya I; Silk MT; Liang Y; Mano R; Chevinsky M; Motzer RJ; Solomon SB; Cheng EH; Durack JC; Coleman JA; Russo P; Hsieh JJ
Cancer Med; 2014 Dec; 3(6):1485-92. PubMed ID: 25124064
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
37. Modeling Renal Cell Carcinoma in Mice:
Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
[TBL] [Abstract][Full Text] [Related]
38.
Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P
Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800
[TBL] [Abstract][Full Text] [Related]
39. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
40. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Jonasch E; Walker CL; Rathmell WK
Nat Rev Nephrol; 2021 Apr; 17(4):245-261. PubMed ID: 33144689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
